Proton pump inhibitor on susceptibility to COVID-19 and its severity: a systematic review and meta-analysis
| Autor: | I Dewa Nyoman Wibawa, Joshua Henrina, Raymond Pranata, Raden Ayu Tuty Kuswardhani, Ian Huang, Antonia Anna Lukito, Sherly Lawrensia, Michael Anthonius Lim |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Gastrointestinal medicine.medical_specialty medicine.drug_class medicine.medical_treatment Proton-pump inhibitor Proton pump inhibitor Severity of Illness Index Article Severity 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Infection rate Risk Factors Internal medicine Diabetes mellitus Diabetes Mellitus medicine Humans Renal Insufficiency Chronic Aged Aged 80 and over Pharmacology Mechanical ventilation SARS-CoV-2 business.industry COVID-19 Proton Pump Inhibitors General Medicine Middle Aged medicine.disease Coronavirus Pneumonia Susceptibility 030220 oncology & carcinogenesis Meta-analysis Hypertension Cohort Disease Progression Female business 030217 neurology & neurosurgery Kidney disease |
| Zdroj: | Pharmacological Reports |
| ISSN: | 2299-5684 1734-1140 |
| DOI: | 10.1007/s43440-021-00263-x |
| Popis: | Background The negative impacts of proton pump inhibitor (PPI), including the risk of pneumonia and mortality, have been reported previously. This meta-analysis aimed to address the current interest of whether the administration of PPI could increase the susceptibility and risk of poor outcome in COVID-19. Methods We performed a systematic literature search from PubMed, Embase, EBSCOhost, and EuropePMC databases up until 3 December 2020. The main outcome was composite poor outcome which comprised of mortality and severe COVID-19. Severe COVID-19 in this study was defined as patients with COVID-19 that fulfill the criteria for severe CAP, including the need for intensive unit care or mechanical ventilation. The secondary outcome was susceptibility, based on cohort comparing COVID-19 positive and COVID-19 negative participants. Results There were a total of 290,455 patients from 12 studies in this meta-analysis. PPI use was associated with increased composite poor outcome (OR 1.85 [1.13, 3.03], p = 0.014; I2 90.26%). Meta-regression analysis indicate that the association does not vary by age (OR 0.97 [0.92, 1.02], p = 0.244), male (OR 1.05 [0.99, 1.11], p = 0.091), hypertension (OR 9.98 [0.95, 1.02], p = 0.317), diabetes (OR 0.99 [0.93, 1.05], p = 0.699), chronic kidney disease (OR 1.01 [0.93, 1.10], p = 0.756), non-steroidal anti-inflammatory drug use (OR 1.02 [0.96, 1.09], p = 0.499), and pre-admission/in-hospital PPI use (OR 0.77 [0.26, 2.31], p = 0.644). PPI use was not associated with the susceptibility to COVID-19 (OR 1.56 [0.48, 5.05], p = 0.46; I2 99.7%). Conclusion This meta-analysis showed a potential association between PPI use and composite poor outcome, but not susceptibility. PROSPERO ID: CRD42020224286. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink